PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
35.97%
Some net income increase while TRVN is negative at -17.46%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Deferred tax of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-6.03%
Negative yoy SBC while TRVN is 1.67%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-150.99%
Both reduce yoy usage, with TRVN at -23057.14%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-123.01%
Both negative yoy AP, with TRVN at -118.46%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-179.37%
Both reduce yoy usage, with TRVN at -9290.32%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-42.60%
Negative yoy while TRVN is 4.59%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-14.43%
Both yoy CFO lines are negative, with TRVN at -44.71%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both yoy lines negative, with TRVN at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.